← All trials
NCT05257824
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2022
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Feb 25, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 528
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- University of UlsanCollaborator
- Keimyung UniversityCollaborator
- Pusan National UniversityCollaborator
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversityReponsible party - principal investigator
- Seoul National UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yonsei UniversityCollaborator
- Soonchunhyang UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yonsei UniversityCollaborator
- Seoul National UniversityOfficial
- Seoul National UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.